期刊文献+

二甲双胍联合西格列汀治疗早期2型糖尿病的临床疗效 被引量:2

The Effect Observation of Metformin Combined with Sitagliptin in Treatment of Early Type 2 Diabetes Mellitus
在线阅读 下载PDF
导出
摘要 目的观察二甲双胍联合西格列汀治疗早期2型糖尿病的临床疗效。方法选取2008年11月—2012年11月我院收治的早期2型糖尿病患者160例,将其随机分为研究组与对照组,研究组采用二甲双胍与西格列汀联合治疗,对照组单用二甲双胍治疗,比较两组治疗前与治疗后2个月、4个月血糖改善情况和不良反应。结果两组治疗前空腹血糖(FBG)、餐后2h血糖(2hPBG)及糖化血红蛋白(HbA1c)比较,差异无统计学意义(P>0.05);治疗2个月和4个月后,研究组上述指标低于对照组,差异有统计学意义(P<0.05);研究组和对照组治疗中不良反应发生率分别为7.5%和8.8%,两组比较差异无统计学意义(P>0.05)。结论二甲双胍联合西格列汀治疗早期2型糖尿病疗效显著,不良反应少,值得临床推广。 Objective To observe curative effect of metformin combined with sitagliptin in treatment of early type 2 diabetes mellitus.Methods From November 2008 to November 2012 in our hospital treated 160 cases of early type 2 diabetic patients,which were randomly divided into study group and control group,the study group using metformin and sitagliptin treatment,control group with single metformin treatment,compared two groups of patients before and after treatment,2 months,4 months of glycemic control and adverse reaction.Results The two groups before treatment,fasting blood glucose(FBG),2h postprandial plasma glucose(2hPBG) and glycosylated hemoglobin(HbA1c),there was no significant difference(P 0.05);treatment of 2 months and 4 months after the index,the study group than in the control group,the difference was statistically significant(P 0.05);the study group and the control group in the treatment of adverse reaction incidence rates were 7.5% and 8.8%,the difference between the two groups was not statistically significant(P 0.05).Conclusion Metformin combined with sitagliptin treatment of type 2 diabetes curative effect,less adverse reaction,is worth the clinical promotion.
出处 《实用心脑肺血管病杂志》 2013年第7期81-82,共2页 Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词 二甲双胍 西格列汀 糖尿病 2型 治疗结果 Metformin Sitagliptin Diabetes mellitus type 2 Treatment outcome
  • 相关文献

参考文献5

二级参考文献35

  • 1本刊编辑部.二甲双胍的作用和疗效[J].中华糖尿病杂志(1006-6187),2005,13(1):60-60. 被引量:3
  • 2刘英敏.二甲双胍的临床合理应用与再评价[J].实用糖尿病杂志,1998,2:21-21.
  • 3Boudina S, Abel ED. Diabetic cardiomyopathy revisited [J]. Circulation, 2007, 115: 3213-23.
  • 4Doehner W, Ravchhaus M, Godslandi F, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNFalpha [J]. J Int J Cardiol, 2002, 83:73-81.
  • 5Reaven GM, Johnston P, Hollenbeck CB, et al. Combined metforminsulfonylurea treatment of patients with noninsulindependent diabetes in fair to poor glycemic control [J]. J Clin Endocrinol Metab, 1992, 74: 1020-1026.
  • 6Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients [J]. Dbetes Care, 1990, 13:1-8.
  • 7Wu MS, Johnston P, Sheu WH, et al. The effects of metformin on glycemic control and serum lipids ininsulintreated NIDDM patientswith suboptimal metabolic control [J]. Diabetes Care, 1998, 21 : 701-705.
  • 8ShulmanGI. Cellular mechanisms of insulin resistance in humans [J]. Am J Cardiol, 1999, 84:3-10.
  • 9Schultes B, Oltmanns KM, Kern W, et al. Modulation of hunger by plasma glucose and metformin [J]. J Clin Endocrinol Metab, 2003, 88 (3): 1133-1141.
  • 10Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagonlike peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects [J]. Diabetes Care, 2001, 24 (3) : 489-494.

共引文献103

同被引文献34

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部